A multidisciplinary team (MDT) approach is necessary in treating metastatic breast cancer in order to provide optimal care. This article, published in JNCCN, reviews the findings of an educational needs assessment of the multidisciplinary breast cancer management team.
Long-term follow-up data from randomized trials on Hodgkin lymphoma support current risk-adapted therapeutic approaches for early-stage disease.
This PD-1 inhibitor is effective for treating melanoma, though it can be highly toxic and there is a lack of biomarkers for predicting a response.
Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.
Atezolizumab is the most recent in a line of immune checkpoint inhibitors approved for patients with NSCLC.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Wildes about the management of multiple myeloma among older patients.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- In Focus: Atezolizumab for Non-small Cell Lung Cancer
- Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients
- FDA Warns 14 Companies To Stop Selling Illegal Cancer Treatments
- PSA Density More Accurate Than PSA for Predicting Prostate Cancer
- ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer
- Chromosome Instability Associated With Death in NSCLC
- miRNA Repression May Drive Aberrant Signaling in MM
- Nivolumab Fails as Single-agent Treatment for Advanced Uterine Leiomyosarcoma
- Hodgkin Lymphoma: Risk-adapted Therapy Recommended
- Pembrolizumab Effective Regardless of Prior Therapy in Classical Hodgkin Lymphoma